110 related articles for article (PubMed ID: 29137241)
1. ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activity
Yin G; Fan J; Zhou W; Ding Q; Zhang J; Wu X; Tang P; Zhou H; Wan B; Yin G
Oncotarget; 2017 Oct; 8(47):82027-82036. PubMed ID: 29137241
[TBL] [Abstract][Full Text] [Related]
2. The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415.
Zhang W; Chen B; Zhang Y; Li K; Hao K; Jiang L; Wang Y; Mou X; Xu X; Wang Z
Biochem Biophys Res Commun; 2017 Jun; 487(3):494-499. PubMed ID: 28366631
[TBL] [Abstract][Full Text] [Related]
3. The anti-osteosarcoma cell activity by a mTORC1/2 dual inhibitor RES-529.
Hu X; Wang Z; Chen M; Chen X; Liang W
Biochem Biophys Res Commun; 2018 Mar; 497(2):499-505. PubMed ID: 29432734
[TBL] [Abstract][Full Text] [Related]
4. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
[TBL] [Abstract][Full Text] [Related]
5. AMPK activation by GSK621 inhibits human melanoma cells in vitro and in vivo.
Chen L; Chen Q; Deng G; Kuang S; Lian J; Wang M; Zhu H
Biochem Biophys Res Commun; 2016 Nov; 480(4):515-521. PubMed ID: 27751856
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mTOR signaling by oleanolic acid contributes to its anti-tumor activity in osteosarcoma cells.
Zhou R; Zhang Z; Zhao L; Jia C; Xu S; Mai Q; Lu M; Huang M; Wang L; Wang X; Jin D; Bai X
J Orthop Res; 2011 Jun; 29(6):846-52. PubMed ID: 21246613
[TBL] [Abstract][Full Text] [Related]
7. ERK1/2 activation mediated by the nutlin‑3‑induced mitochondrial translocation of p53.
Lee SY; Shin SJ; Kim HS
Int J Oncol; 2013 Mar; 42(3):1027-35. PubMed ID: 23314357
[TBL] [Abstract][Full Text] [Related]
8. Autophagy inhibition sensitizes WYE-354-induced anti-colon cancer activity in vitro and in vivo.
Wang L; Zhu YR; Wang S; Zhao S
Tumour Biol; 2016 Sep; 37(9):11743-11752. PubMed ID: 27020593
[TBL] [Abstract][Full Text] [Related]
9. C6 ceramide sensitizes pemetrexed-induced apoptosis and cytotoxicity in osteosarcoma cells.
Zhu X; Du X; Deng X; Yi H; Cui S; Liu W; Shen A; Cui Z
Biochem Biophys Res Commun; 2014 Sep; 452(1):72-8. PubMed ID: 25152399
[TBL] [Abstract][Full Text] [Related]
10. Preclinical study of CC223 as a potential anti-ovarian cancer agent.
Jin Z; Niu H; Wang X; Zhang L; Wang Q; Yang A
Oncotarget; 2017 Aug; 8(35):58469-58479. PubMed ID: 28938571
[TBL] [Abstract][Full Text] [Related]
11. SphK2 over-expression promotes osteosarcoma cell growth.
Xu D; Zhu H; Wang C; Zhao W; Liu G; Bao G; Cui D; Fan J; Wang F; Jin H; Cui Z
Oncotarget; 2017 Dec; 8(62):105525-105535. PubMed ID: 29285269
[TBL] [Abstract][Full Text] [Related]
12. Liposomal short-chain C6 ceramide induces potent anti-osteosarcoma activity in vitro and in vivo.
Zhai L; Sun N; Han Z; Jin HC; Zhang B
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):274-80. PubMed ID: 26505795
[TBL] [Abstract][Full Text] [Related]
13. Butein sensitizes HeLa cells to cisplatin through the AKT and ERK/p38 MAPK pathways by targeting FoxO3a.
Zhang L; Yang X; Li X; Li C; Zhao L; Zhou Y; Hou H
Int J Mol Med; 2015 Oct; 36(4):957-66. PubMed ID: 26310353
[TBL] [Abstract][Full Text] [Related]
14. 3-Hydroxyflavone inhibits human osteosarcoma U2OS and 143B cells metastasis by affecting EMT and repressing u-PA/MMP-2 via FAK-Src to MEK/ERK and RhoA/MLC2 pathways and reduces 143B tumor growth in vivo.
Lu KH; Chen PN; Hsieh YH; Lin CY; Cheng FY; Chiu PC; Chu SC; Hsieh YS
Food Chem Toxicol; 2016 Nov; 97():177-186. PubMed ID: 27600294
[TBL] [Abstract][Full Text] [Related]
15. Autophagy inhibition sensitizes LY3023414-induced anti-glioma cell activity
Zheng L; Li H; Mo Y; Qi G; Liu B; Zhao J
Oncotarget; 2017 Nov; 8(58):98964-98973. PubMed ID: 29228741
[TBL] [Abstract][Full Text] [Related]
16. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
[TBL] [Abstract][Full Text] [Related]
17. Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014.
Huo HZ; Zhou ZY; Wang B; Qin J; Liu WY; Gu Y
Biochem Biophys Res Commun; 2014 Jan; 443(2):406-12. PubMed ID: 24309100
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
Murayama T; Kawasoe Y; Yamashita Y; Ueno Y; Minami S; Yokouchi M; Komiya S
Anticancer Res; 2008; 28(4B):2147-54. PubMed ID: 18751388
[TBL] [Abstract][Full Text] [Related]
19. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
Yang R; Piperdi S; Gorlick R
Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
[TBL] [Abstract][Full Text] [Related]
20. MEK-ERK inhibition potentiates WAY-600-induced anti-cancer efficiency in preclinical hepatocellular carcinoma (HCC) models.
Wang K; Fan Y; Chen G; Wang Z; Kong D; Zhang P
Biochem Biophys Res Commun; 2016 May; 474(2):330-337. PubMed ID: 27107695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]